Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 4/20 | 0.31 |
| ▸ | RARB | P10826 | 4/20 | 0.31 |
| ▸ | RARG | P13631 | 4/20 | 0.31 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252678 | 0.92 | KDR (0.37) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL30467751 | 0.89 | KDR (0.36) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252269 | 0.86 | DHFR (0.40) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252504 | 0.83 | SCN9A (0.36) | ALOX5APFEN1PLGF12F11 | |
| SCHEMBL30452320 | 0.83 | SCN9A (0.36) | ALOX5APFEN1PLGF12F11 | |
| SCHEMBL24252712 | 0.83 | SCN9A (0.32) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL26771059 | 0.83 | AR (0.33) | RARARARBRARG | |
| Formic Acid SCHEMBL30451288 | 0.82 | DHFR (0.37) | PLGF12F11KLKB1PRSS1 | |
| Formic Acid SCHEMBL25242412 | 0.82 | DHFR (0.37) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252263 | 0.81 | MAP4K4 (0.37) | PLGF12F11KLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | ALOX5AP 246/4885FEN1 2638/4885PLG 260/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | ALOX5AP 246/4885FEN1 2638/4885PLG 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.